A network meta-analysis of four randomized trials found no robust superiority among CAR-T cells, bispecific antibodies, and traditional chemotherapy combinations in early relapsed multiple myeloma. Treatment selection should rest on individual factors, toxicity profiles, and access rather than efficacy data alone.
Researchers conducted a systematic review and network meta-analysis comparing three T-cell-redirecting approaches—ciltacabtagene autoleucel (cilta-cel), teclistamab-daratumumab, and talquetamab-daratumumab—against standard daratumumab-pomalidomide-dexamethasone regimens in patients with early relapsed multiple myeloma (defined as relapse after at least one prior line of therapy). The analysis pooled data from four randomized phase 3 trials involving 2,174 patients, reconstructing individual patient time-to-event data from published survival curves to enable indirect comparisons across studies.
The headline result: no treatment hierarchy could be established with confidence. Under fixed-effects modeling, teclistamab-daratumumab appeared to rank first for progression-free survival with a P-score of 98% (meaning it outranked competing treatments in probabilistic ranking). However, this apparent superiority collapsed when the analysis accounted for between-trial heterogeneity. The control-arm median progression-free survival ranged dramatically from 9.9 to 24.4 months across trials (I-squared = 91%), indicating substantial variation in patient populations, disease characteristics, or trial conduct. Once random-effects assumptions were applied, all pairwise contrasts crossed unity (their 95% credible intervals included 1.0), meaning none demonstrated clear separation. Teclistamab-daratumumab versus cilta-cel showed a hazard ratio of 0.62 (95% credible interval 0.21 to 1.81)—an estimate wide enough to span both substantial benefit and substantial harm.
Overall survival findings were similarly inconclusive. Teclistamab-daratumumab versus cilta-cel yielded a hazard ratio of 0.94 (0.55 to 1.62), and restricted mean survival gains over control ranged from 0.7 to 1.6 months at 24 months—gains that are unlikely to be clinically meaningful. Rankings for overall survival ranged between 56% and 70% across regimens, indicating near-equivalence in probabilistic terms. The authors explicitly note that "randomized evidence in early relapse does not establish an efficacy hierarchy among these regimens."
Safety data differed across modalities but could not be reliably compared across trials due to variation in how adverse events were monitored and reported. Cost-consequence analysis found cilta-cel lowest on a per-progression-free-month basis when computed against standardized population denominators, but this advantage narrowed substantially under realistic treatment duration scenarios. The stark conclusion: until head-to-head comparative data exist, efficacy alone cannot guide treatment selection.
This analysis underscores a critical reality in advanced oncology: more options do not automatically mean clearer answers. For patients and clinicians facing early relapsed multiple myeloma, the implications are practical:
| Detail | Finding |
|---|---|
| Study type | Systematic review and Bayesian network meta-analysis with frequentist sensitivity analysis |
| Sample size | 2,174 patients across four randomized phase 3 trials |
| Trials included | Ciltacabtagene autoleucel (cilta-cel), teclistamab-daratumumab, talquetamab-daratumumab (with/without pomalidomide) versus standard control |
| Primary outcome | Progression-free survival (PFS) |
| Secondary outcomes | Overall survival, restricted mean survival at 24 and 36 months, safety, cost-consequence analysis |
| Key finding | No robust efficacy hierarchy; all pairwise contrasts crossed unity under random-effects modeling |
| PFS control-arm range | 9.9 to 24.4 months (high heterogeneity, I-squared 91%) |
| OS hazard ratio (teclistamab vs. cilta-cel) | 0.94 (95% CrI 0.55 to 1.62) |
| Mean OS gain over control at 24 months | 0.7 to 1.6 months |
| Journal | Journal of Hematology & Oncology |
| Date published | 2025 |
| PROSPERO registration |
Tisi, M. C., et al. (2025). T-cell-redirecting therapies in early relapsed multiple myeloma: a systematic review and network meta-analysis. *Journal of Hematology & Oncology*, 18, 8.
ProtocolEngine provides general health information based on published research. This is not medical advice. Consult a healthcare professional before starting any supplement or health protocol.